tcY-NH2
CAT:
804-HY-P1263
Size:
Inquire
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


tcY-NH2
UNSPSC Description:
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) is a potent selective PAR4 antagonist peptide. tcY-NH2 inhibits thrombin- and AY-NH2-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology[1][2][6].Target Antigen:
Protease Activated Receptor (PAR)Type:
PeptidesRelated Pathways:
GPCR/G ProteinApplications:
Metabolism-protein/nucleotide metabolismField of Research:
Metabolic Disease; Inflammation/ImmunologyAssay Protocol:
https://www.medchemexpress.com/tcy-nh2.htmlSolubility:
10 mM in DMSOSmiles:
OC(C=C1)=CC=C1C[C@H](NC(/C=C/C2=CC=CC=C2)=O)C(N3[C@@H](CCC3)C(NCC(N[C@@H](CCCCN)C(N[C@H](C(N)=O)CC4=CC=CC=C4)=O)=O)=O)=OMolecular Weight:
739.86References & Citations:
[1]Morley D Hollenberg, et al. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol. 2004 Oct;143(4):443-54.|[2]L Ma, et al. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol. 2001 Oct;134(4):701-4.|[3]Hongbo Fang, et al. Blocking protease-activated receptor 4 alleviates liver injury induced by brain death. Biochem Biophys Res Commun. 2022 Mar 5;595:47-53. |[4]Matthias Bock, et al. Platelets differentially modulate CD4 + Treg activation via GPIIa/IIIb-, fibrinogen-, and PAR4-dependent pathways. Immunol Res. 2022 Apr;70(2):185-196. |[5]Jennifer L Strande, et al. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther. 2008 Mar;324(3):1045-54. |[6]Lindisley F Gomides, et al. Blockade of proteinase-activated receptor 4 inhibits neutrophil recruitment in experimental inflammation in mice. Inflamm Res. 2014 Nov;63(11):935-41.Shipping Conditions:
Room temperatureClinical Information:
No Development ReportedCAS Number:
327177-34-4